$BVNRY

Bavarian Nordic completes additional repurchases under its DKK 200M buyback program, accumulating 900,295 shares at DKK 190.54 average price through May 1, 2026.

Bavarian Nordic nears completion of DKK 200M share buyback program, having repurchased 900,295 shares representing 3.28% of share capital.

Bavarian Nordic repurchased 179,730 shares at 191.09 DKK average price in April. Program now totals 825,996 shares worth 157.8M DKK since March launch.

Bavarian Nordic completes latest share buyback tranche, repurchasing 179,730 shares at DKK 191.09, bringing total program deployment to DKK 157.8 million.

Bavarian Nordic held its annual meeting April 21, approving 2025 results and expanding the board to seven members, but shareholders rejected the compensation report in non-binding vote.

Bavarian Nordic shareholders rejected the 2025 Remuneration Report at April AGM, while approving other governance matters including board elections and capital authorizations.

Bavarian Nordic secures Swiss regulatory approval for chikungunya vaccine VIMKUNYA, marking fourth major market clearance in 2025 following FDA, EMA, and MHRA approvals.

Bavarian Nordic's chikungunya vaccine VIMKUNYA wins Swiss regulatory approval, marking the fourth major authorization in 2025 following FDA, EMA, and MHRA clearances.

Bavarian Nordic initiates share buyback program worth DKK 200M through May 2026, purchasing 40,086 shares at average price of DKK 177.15 on first day.

Bavarian Nordic repurchased 40,086 shares at DKK 177.15 average price under its DKK 200 million buyback program, bringing total treasury holdings to 1.74M shares.